Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Juncos

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Neurology|August 1, 1986
Huntington's disease: effect of cysteamine, a somatostatin-depleting agentC Shults, L Steardo, P Barone, et al.
Journal of Medical Genetics|February 1, 2008
Detection of early FXTAS motor symptoms using the CATSYS computerised neuromotor test batteryE G Allen, J Juncos, R Letz, et al.
Annals of the New York Academy of Sciences|January 1, 1985
Cholecystokinin-mediated synaptic function and the treatment of neuropsychiatric diseaseT N Chase, P Barone, G Bruno, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 4, 2012
Daytime alertness in Parkinson's disease: potentially dose-dependent, divergent effects by drug classDonald L Bliwise, Lynn Marie Trotti, Anthony G Wilson, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 24, 2001
Dorsal subthalamotomy for Parkinson's diseaseL Alvarez, R Macias, J Guridi, et al.
Parkinsonism & Related Disorders|April 1, 2014
Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinson's diseaseA J H Moonen, A Wijers, A F G Leentjens, et al.
Neurology|April 13, 2012
A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson diseaseI H Richard, M P McDermott, R Kurlan, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Neurology|August 1, 1986
Huntington's disease: effect of cysteamine, a somatostatin-depleting agentC Shults, L Steardo, P Barone, et al.
Journal of Medical Genetics|February 1, 2008
Detection of early FXTAS motor symptoms using the CATSYS computerised neuromotor test batteryE G Allen, J Juncos, R Letz, et al.
Annals of the New York Academy of Sciences|January 1, 1985
Cholecystokinin-mediated synaptic function and the treatment of neuropsychiatric diseaseT N Chase, P Barone, G Bruno, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 4, 2012
Daytime alertness in Parkinson's disease: potentially dose-dependent, divergent effects by drug classDonald L Bliwise, Lynn Marie Trotti, Anthony G Wilson, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 24, 2001
Dorsal subthalamotomy for Parkinson's diseaseL Alvarez, R Macias, J Guridi, et al.
Parkinsonism & Related Disorders|April 1, 2014
Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinson's diseaseA J H Moonen, A Wijers, A F G Leentjens, et al.
Neurology|April 13, 2012
A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson diseaseI H Richard, M P McDermott, R Kurlan, et al.
Pageof 2